"The US Food and Drug Administration (FDA) today granted accelerated approval for osimertinib (Tagrisso, AstraZeneca), previously known as AZD9291, for the treatment of a specific type of advanced non-small-cell lung cancer.
NoneThis monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/23/2015
Additional Gilotrif Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.